Cargando…

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Judge, Daniel P., Kristen, Arnt V., Grogan, Martha, Maurer, Mathew S., Falk, Rodney H., Hanna, Mazen, Gillmore, Julian, Garg, Pushkal, Vaishnaw, Akshay K., Harrop, Jamie, Powell, Christine, Karsten, Verena, Zhang, Xiaoping, Sweetser, Marianne T., Vest, John, Hawkins, Philip N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242280/ https://www.ncbi.nlm.nih.gov/pubmed/32062791 http://dx.doi.org/10.1007/s10557-019-06919-4

Ejemplares similares

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
por: Gillmore, Julian D, et al.
Publicado: (2015)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis
por: Zanazzi, George, et al.
Publicado: (2019)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

Modified Technique of Ex-PRESS(®) Filtration Device Combined with a Scleral Pocket for Hereditary Transthyretin Amyloidosis (hATTR) Secondary Open-Angle Glaucoma
por: Vieira, Rita, et al.
Publicado: (2023)

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis
por: Connolly, Mark P., et al.
Publicado: (2019)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers
por: Luigetti, Marco, et al.
Publicado: (2020)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review
por: Aldinc, Emre, et al.
Publicado: (2023)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
por: Sutherland, Jessica E., et al.
Publicado: (2020)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis
por: Ihse, Elisabet, et al.
Publicado: (2010)

Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
por: Hsu, Hui-Ching, et al.
Publicado: (2017)

In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR)
por: Wollenweber, Tim, et al.
Publicado: (2020)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Analysis of disease progression in patients with transthyretin cardiac amyloidosis
por: Gilmore, Julian D, et al.
Publicado: (2015)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)
por: Nakase, Taku, et al.
Publicado: (2019)

Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?
por: Duran, Jessica M., et al.
Publicado: (2022)

Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
por: Gertz, Morie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jroehq66ogqsuih3raulasceo2